Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — Investor Presentation (June 2026)
16 slides from Genetic Signatures's investor presentation, Jun 10, 2026
Slide 1: 90-day Strategic Review: Positioning for Growth
For personal use only 90- day Strategic Review Positioning for Growth 10 June 2026
Slide 2: Disclaimer
Investor presentation Disclaimer For personal use only June 2026 This presentation has been prepared by Genetic Signatures Limited ACN 095 913 205 (the Company or GSS) and approved by the Board of Directors for release . It comprises written materials/slides for a verbal presentation concerning the
Slide 3: Executive Summary
Executive Summary For personal use only Investor presentation June 2026 WHAT WE FOUND WHAT WE HAVE DONE WHERE WE ARE GOING • Established customer relationships • $5M reduction in fixed costs with full • Implementing profitability - first with meaningful revenue effect from FY2027 commercial model •
Slide 4: Technology asset: 3base
What We Found For personal use only Investor presentation June 2026 Findings: • Proprietary 3base ® chemistry is a defensible scientific differentiator with superior sensitivity in infectious disease diagnostics and has potential in other applications. • The EasyScreen assay range is validated acros
Slide 5: Revenue and existing supply agreements
What We Found For personal use only Investor presentation June 2026 Findings: • GSS has long - term contracts with key customers in Australia and EMEA delivering more than 500,000 tests per year • Revenue diversity is limited which is a key organisational risk • Legacy relationships meant some suppl
Slide 6: Organisational and cost structure
What We Found For personal use only Investor presentation June 2026 Findings: • Deep talent pool in molecular diagnostics; long term committed employees • Overlapping functional units in research and development, while insufficient resources in sales and business development • Spread too thinly, the
Slide 7: Product portfolio
What We Found For personal use only Investor presentation June 2026 Findings: • The Company’s current EasyScreen pathogen detection kits are different in each territory resulting in additional regulatory, marketing and production costs Product • The product perform well in the field, but will requir
Slide 8: US market
What We Found For personal use only Investor presentation June 2026 Findings: • The FDA 510(k) clearance for the EasyScreen Parasite Detection kit was a genuine milestone • The US market entry had limited success for several reasons: reimbursement challenges for the full pathogen portfolio, differen
Slide 9: Instrumentation strategy: Optimus Prime
What We Found For personal use only Investor presentation June 2026 Findings: • Addressing the requirements of high - throughput US labs has been a key driver for the Optimus Prime project Instrumentation Opportunity: strategy: • Pausing the Optimus Prime project follows the pause of the US market a
Slide 10: Reset organisational and cost structure
What We Have Done For personal use only Investor presentation June 2026 90 - Day Report Card: • Completed rightsizing of the Company and completed a line - by- line expenditure review with total annualised savings of $5M • Established purchasing processes and controls that are expected to result in
Slide 11: Secured long term supply agreements
What We Have Done For personal use only Investor presentation June 2026 90 Day Report Card: • Signed strategically significant Danish contract with Hvidovre Hospital demonstrating traction in the EMEA market and opening new opportunities in Europe Secured long • Secured long term supply agreement in
Slide 12: Product and instrumentation strategy
What We Have Done For personal use only Investor presentation June 2026 90 Day Report Card: • Completed product and instrumentation strategy to secure supply for existing long - term contracts, as well as potential new EMEA, APAC and Australian customers Product and • New product development strateg
Slide 13: Where We Are Going: Strategic Framework
Where We Are Going For personal use only Investor presentation June 2026 Strategic Framework HORIZON 1 HORIZON 2 HORIZON 3 STABILISE OPTIMISE SCALE Months 1 – 6 Months 4 – 12 Months 9 – 24 DONE/UNDERWAY NEXT PLANNED Secure the foundation Extract full value from assets Build the growth engine • Imple
Slide 14: Experienced Executive Team
Experienced Executive Team For personal use only Investor presentation June 2026 Maria Halasz 20+ years' experience in senior management roles in the life sciences sector including as CEO of a listed company, with experience in licensing diagnostics CEO and leading global product launches Susanne Pe
Slide 15: Summary
Summary For personal use only Investor presentation June 2026 Stabilised before optimising and scaling Right cost base, stabilised existing customer relationships, 1 realigned organisational structure and sustainable controls and reporting systems – increased runway Profitability over revenue Large
Slide 16: Q&A
For personal use only Q&A Maria Halasz Chief Executive Officer investors@geneticsignatures.com P: +61 (0)2 9870 7580 Visit us geneticsignatures.com Follow us 16
Genetic Signatures — Investor Presentation (June 2026) on 6ix